news

TD2 and Navigating Cancer team up to bring patient-reported outcomes to clinical trials

0
SHARES

Posted: 20 April 2015 |

TD2 and Navigating Cancer are teaming up to improve patient engagement in trials and bring patient-reported outcomes to the clinical trials process…

TD2, an oncology development organisation, and Navigating Cancer, the leading web-based patient care and engagement solution for oncology clinics, have entered in to a  partnership to improve the engagement of patients in clinical trials and bring patient-reported outcomes to the clinical trials process.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

mobile-td2

Patients participating in TD2-managed clinical trials will be able to give feedback through a simple-to-use mobile application

The integration with Navigating Cancer’s mobile care management solution will allow patients participating in TD2-managed clinical trials to record adherence and report how they are feeling in real time through a simple-to-use mobile application.  This information will be provided to TD2’s participating oncology trial sites to enhance the care of patients enrolled in clinical studies.  This access to patient-reported experiences on emerging therapies will provide biotechnology and pharmaceutical companies with new insights that could be used to improve trial designs, develop unique clinical trial endpoints and add value in reimbursement decisions.

TD2 will use real-time patient reported data for more efficient patient-focused clinical trial designs

“Real-time patient reported data using Navigating Cancer’s mobile solution is an important component of the TD2 clinical trial process,” said TD2 CEO Stephen Gately, Ph.D. “ This data will be used to support more efficient patient-focused clinical trial designs, and to potentially identify regulatory opportunities for new medicines that improve patient symptoms and functional abilities.”

“As a company dedicated to improving health outcomes through patient engagement, we believe that providing patients in clinical trials with a convenient, mobile means of reporting their own experiences on an investigative therapy in real time will be a game-changer for patient-centered drug development.” said Gena Cook, CEO of Navigating Cancer.  “We are excited to partner with TD2 to ensure that patient’s experiences are reflected in health outcomes.”

For more information about Navigating Cancer, please visit navigatingcancer.com.

For more about TD2, please visit td2inc.com.

Related topics

Related diseases & conditions

Share via
Share via